{"nctId":"NCT01218308","briefTitle":"A Study to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine in Children","startDateStruct":{"date":"2010-12-09"},"conditions":["Influenza"],"count":5220,"armGroups":[{"label":"FluLaval® Quadrivalent Group","type":"EXPERIMENTAL","interventionNames":["Biological: FluLaval® Quadrivalent"]},{"label":"Havrix Group","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Havrix™"]}],"interventions":[{"name":"FluLaval® Quadrivalent","otherNames":["Quadrivalent seasonal influenza vaccine GSK2282512A"]},{"name":"Havrix™","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects who the investigator believes that they and/or their parent(s) or legally acceptable representative(s) can and will comply with the requirements of the protocol.\n* A male or female child aged between 3 and 8 years inclusive at the time of the first vaccination; children are eligible regardless of history of administration of influenza vaccine in a previous season. However, subjects who have received any seasonal or pandemic influenza vaccine within 6 months preceding the first dose of study vaccine will not be enrolled.\n* Written informed consent obtained from the subject/from the parent(s)/legally acceptable representative(s) of the subject.\n* Written assent obtained from the subject if/as required by local regulations.\n* Subjects in stable health as determined by investigator's clinical examination and assessment of subjects' medical history.\n* Access to a consistent means of telephone contact\n\nExclusion Criteria:\n\n* Child in care.\n* Use of an investigational or non-registered product other than the study vaccines within 30 days before study vaccination or planned use during study period. Routine registered childhood vaccinations are permitted.\n* Prior receipt of any seasonal or pandemic influenza vaccine within 6 months preceding the first dose of study vaccine, or planned use of such vaccines during the study period. Prior receipt of more than one dose of a licensed hepatitis A vaccine, with the first dose administered at \\>=12 months of age.\n* Chronic administration of immunosuppressants or other immune-modifying drugs within 6 months prior to the first vaccine dose.\n* Administration of immunoglobulins and/or any blood products within the 3 months preceding the first dose of study vaccine or planned administration during the study period.\n* History of Guillain-Barre syndrome within 6 weeks of receipt of prior influenza virus vaccine.\n* Any known or suspected allergy to any constituent of influenza vaccines ; a history of anaphylactic-type reaction to constituent of vaccine; or a history of severe adverse reaction to a previous influenza vaccine.\n* Fever at the time of enrolment.\n* Acute disease at the time of enrolment.\n* Any significant disorder of coagulation or treatment with Coumadin derivatives or heparin.\n* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.\n* Ongoing aspirin therapy.\n* Any other condition which, in the opinion of the Investigator, prevents the subject from participating in the study.","healthyVolunteers":true,"sex":"ALL","minimumAge":"3 Years","maximumAge":"8 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects Reporting at Least One Confirmed Occurrence of Influenza A or B.","description":"To confirm influenza A and/or B disease, a positive reverse transcriptase polymerase chain reaction (RT-PCR) result for influenza A or B virus from a nose and throat swab obtained concurrently with an influenza like illness (ILI) was required. ILI was defined as the presence of an oral or axillary temperature ≥ 37.8 degrees Celsius (°C) in the presence of at least one of the following symptoms on the same day: cough, sore throat, runny nose or nasal congestion.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null},{"groupId":"OG001","value":"128","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting at Least One Moderate to Severe Occurrence of Influenza A or B.","description":"To confirm influenza A and/or B disease moderate to severe cases, a positive RT-PCR result for influenza A or B virus from a nose and throat swab obtained concurrently with an ILI was required. Moderate to severe influenza was defined as RT-PCR-confirmed ILI with:\n\n* Fever \\>39°C, and/or at least one of the following manifestations,\n* Physician-verified shortness of breath, pulmonary congestion, pneumonia, bronchiolitis, bronchitis, wheezing, croup, or acute otitis media, and/or one of the following,\n* Physician-diagnosed serious extra-pulmonary complication of influenza, including myositis, encephalitis, seizure, or myocarditis","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"52","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting at Least One Culture Confirmed Occurrence of Influenza A or B Due to Antigenically Matched Strain.","description":"To confirm influenza A and/or B disease due to antigenically matched strain, a positive reverse transcriptase polymerase chain reaction (RT-PCR) result for influenza A or B virus from a nose and throat swab obtained concurrently with an influenza like illness (ILI) was required. ILI was defined as the presence of an oral or axillary temperature ≥ 37.8 degrees Celsius (°C) in the presence of at least one of the following symptoms on the same day: cough, sore throat, runny nose or nasal congestion.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"56","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting at Least One Culture Confirmed Occurrence of Influenza A or B Due to Any Strain.","description":"To confirm influenza A and/or B disease due to any strain, a positive reverse transcriptase polymerase chain reaction (RT-PCR) result for influenza A or B virus from a nose and throat swab obtained concurrently with an influenza like illness (ILI) was required. ILI was defined as the presence of an oral or axillary temperature ≥ 37.8 degrees Celsius (°C) in the presence of at least one of the following symptoms on the same day: cough, sore throat, runny nose or nasal congestion.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"112","spread":null}]}]}]},{"type":"SECONDARY","title":"Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease.","description":"Titers are presented as geometric mean titers (GMTs). The reference cut-off value was the seropositivity cut-off of 1:10. The 4 influenza strains assessed were the Flu A/California/7/09 (H1N1), Flu A/Victoria/210/09 (H3N2), FluB/Brisbane/60/08 (Victoria) and Flu B/Florida/4/06 (Yamagata).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.3","spread":null},{"groupId":"OG001","value":"16.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"318.8","spread":null},{"groupId":"OG001","value":"16.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.3","spread":null},{"groupId":"OG001","value":"28.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"264.7","spread":null},{"groupId":"OG001","value":"30.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.7","spread":null},{"groupId":"OG001","value":"15.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"239.9","spread":null},{"groupId":"OG001","value":"17.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.2","spread":null},{"groupId":"OG001","value":"18.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"361.5","spread":null},{"groupId":"OG001","value":"19.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Seroconverted Subjects Against 4 Strains of Influenza Disease.","description":"A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination titer \\< 1:10 and a post-vaccination titer ≥ 1:40 or a pre-vaccination titer ≥ 1:10 and at least a four-fold increase in post-vaccination titer. The 4 influenza strains assessed were the Flu A/California/7/09 (H1N1), Flu A/Victoria/210/09 (H3N2), FluB/Brisbane/60/08 (Victoria) and Flu B/Florida/4/06 (Yamagata).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"438","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"385","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"425","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"435","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Seroprotected Subjects Against 4 Strains of Influenza Disease.","description":"A seroprotected subject was defined as a vaccinated subject who had a serum HI titer ≥ 1:40. The 4 influenza strains assessed were the Flu A/California/7/09 (H1N1), Flu A/Victoria/210/09 (H3N2), FluB/Brisbane/60/08 (Victoria) and Flu B/Florida/4/06 (Yamagata).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"151","spread":null},{"groupId":"OG001","value":"37","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"451","spread":null},{"groupId":"OG001","value":"39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"205","spread":null},{"groupId":"OG001","value":"63","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"445","spread":null},{"groupId":"OG001","value":"63","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"127","spread":null},{"groupId":"OG001","value":"35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"443","spread":null},{"groupId":"OG001","value":"38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"159","spread":null},{"groupId":"OG001","value":"45","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"452","spread":null},{"groupId":"OG001","value":"45","spread":null}]}]}]},{"type":"SECONDARY","title":"Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease.","description":"The seroconversion factor (SCF) was defined as the fold increase in serum Hemagglutination Inhibition (HI) geometric mean titers (GMTs) post vaccination compared to Day 0. The 4 influenza strains assessed were the Flu A/California/7/09 (H1N1), Flu A/Victoria/210/09 (H3N2), FluB/Brisbane/60/08 (Victoria) and Flu B/Florida/4/06 (Yamagata).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.8","spread":null},{"groupId":"OG001","value":"1.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.9","spread":null},{"groupId":"OG001","value":"1.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.5","spread":null},{"groupId":"OG001","value":"1.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.3","spread":null},{"groupId":"OG001","value":"1.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Haemagglutination Inhibition (HI) Antibody Titers Against Each of the 4 Vaccine Strains","description":"HI antibody titres were expressed as Geometric mean titers (GMTs). The vaccine strains assessed were Flu A/California/7/2009 (H1N1), Flu A/Victoria/210/09 (H3N2), Flu B/Brisbane/60/08 (Victoria) and Flu B/Florida/4/06 (Yamagata).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.5","spread":null},{"groupId":"OG001","value":"16.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"138.6","spread":null},{"groupId":"OG001","value":"23.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.6","spread":null},{"groupId":"OG001","value":"29.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"136.5","spread":null},{"groupId":"OG001","value":"43.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.7","spread":null},{"groupId":"OG001","value":"15.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"110.2","spread":null},{"groupId":"OG001","value":"19.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.1","spread":null},{"groupId":"OG001","value":"18.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"157.0","spread":null},{"groupId":"OG001","value":"21.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Seroconverted Subjects for HI Antibody Titers Against Each of the 4 Vaccine Influenza Strains.","description":"A seroconverted subject was defined as a vaccinated subject with either a pre-vaccination titer less than (\\<) 1:10 and a post-vaccination titer greater than or equal to (≥) 1:40, or a pre-vaccination titer ≥ 1:10 and at least a 4-fold increase in post-vaccination titer. The vaccine strains assessed were Flu A/California/7/09 (H1N1), Flu A/Victoria/210/09 (H3N2), FluB/Brisbane/60/08 (Victoria) and Flu B/Florida/4/06 (Yamagata).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"349","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"290","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"323","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"354","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Seroprotected Subjects for HI Antibody Titers Against Each of the 4 Vaccine Influenza Strains.","description":"A seroprotected subject was defined as a vaccinated subject with a serum HI titer greater than or equal to (≥) 1:40 that usually is accepted as indicating protection in adults. The vaccine strains assessed were Flu A/California/7/09 (H1N1), Flu A/Victoria/210/09 (H3N2), FluB/Brisbane/60/08 (Victoria) and Flu B/Florida/4/06 (Yamagata).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"148","spread":null},{"groupId":"OG001","value":"36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"383","spread":null},{"groupId":"OG001","value":"49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"204","spread":null},{"groupId":"OG001","value":"60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"412","spread":null},{"groupId":"OG001","value":"71","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"123","spread":null},{"groupId":"OG001","value":"32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"374","spread":null},{"groupId":"OG001","value":"39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"153","spread":null},{"groupId":"OG001","value":"43","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"427","spread":null},{"groupId":"OG001","value":"49","spread":null}]}]}]},{"type":"SECONDARY","title":"Seroconversion Factors for HI Antibodies Against 4 Strains of Influenza Disease.","description":"Seroconversion factors were defined as the fold increase in serum HI GMTs post-vaccination compared to Day 0. The 4 influenza strains assessed were the Flu A/California/7/09 (H1N1), Flu A/Victoria/210/09 (H3N2), FluB/Brisbane/60/08 (Victoria) and Flu B/Florida/4/06 (Yamagata).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.9","spread":null},{"groupId":"OG001","value":"1.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","spread":null},{"groupId":"OG001","value":"1.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.0","spread":null},{"groupId":"OG001","value":"1.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.7","spread":null},{"groupId":"OG001","value":"1.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms.","description":"Assessed solicited local symptoms were pain, redness and swelling at the injection site. Any = Incidence of a particular symptom regardless of intensity grade. Grade 3 pain = Cried when limb was moved/spontaneously painful for subjects \\< 5 years of age or significant pain at rest that prevented normal, everyday activities for subjects ≥ 5 years of age. Grade 3 redness/swelling = Redness/swelling above 100 millimeters (mm) of the injection site. All solicited local symptoms were considered related to vaccination.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1215","spread":null},{"groupId":"OG001","value":"888","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms in Subjects Below 5 Years of Age.","description":"Assessed solicited general symptoms were drowsiness, irritability, loss of appetite and temperature. Any = Occurrence of any solicited general symptom regardless of intensity grade and relation to vaccination. Any temperature = Axillary temperature ≥ 38.0 °C. Grade 3 Drowsiness = Drowsiness that prevented normal activity. Grade 3 Irritability = Crying that could not be comforted/prevented normal activity. Grade 3 Loss of appetite = not eating at all. Related = General symptom assessed by the investigator as causally related to the study vaccination. Grade 3 temperature = Axillary temperature ≥ 39.0°C.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"93","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"102","spread":null},{"groupId":"OG001","value":"91","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null},{"groupId":"OG001","value":"59","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"119","spread":null},{"groupId":"OG001","value":"120","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55","spread":null},{"groupId":"OG001","value":"61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74","spread":null},{"groupId":"OG001","value":"74","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"35","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms in Subjects of 5 Years of Age and Above.","description":"Assessed solicited general symptoms were fatigue, gastrointestinal symptoms (Gastro.), headache, joint pain at other location (Joint pain), muscle aches, shivering and temperature. Any = Occurrence of any solicited general symptom regardless of intensity grade or relation to vaccination. Any temperature = Axillary temperature ≥ 38.0 °C. Grade 3 symptom = Symptom that prevented normal activity. Related = Symptom assessed by the investigator as causally related to the vaccination. Grade 3 temperature = Axillary temperature ≥ 39.0°C.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"188","spread":null},{"groupId":"OG001","value":"145","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"101","spread":null},{"groupId":"OG001","value":"78","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"133","spread":null},{"groupId":"OG001","value":"146","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68","spread":null},{"groupId":"OG001","value":"54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"243","spread":null},{"groupId":"OG001","value":"217","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"154","spread":null},{"groupId":"OG001","value":"125","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"143","spread":null},{"groupId":"OG001","value":"93","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null},{"groupId":"OG001","value":"54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"257","spread":null},{"groupId":"OG001","value":"194","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"162","spread":null},{"groupId":"OG001","value":"109","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63","spread":null},{"groupId":"OG001","value":"59","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72","spread":null},{"groupId":"OG001","value":"82","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null},{"groupId":"OG001","value":"37","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs).","description":"Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any = Any unsolicited AE regardless of intensity or relationship to vaccination. Grade 3 = Unsolicited AE that prevented normal activity. Related = Unsolicited AE assessed by the investigator as causally related to the vaccination.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"843","spread":null},{"groupId":"OG001","value":"855","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"37","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any and Related Medically Attended Adverse Events (MAEs).","description":"MAEs were defined as AEs that resulted in medical attention (defined as hospitalization, an emergency room visit or a visit to or from medical personnel for any reason). Any = Any MAE regardless of intensity or relationship to vaccination. Related = MAE assessed by the investigator as causally related to the vaccination.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"792","spread":null},{"groupId":"OG001","value":"749","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any and Related Potential Immune-mediated Diseases (pIMDs).","description":"pIMDs were defined as a subset of AEs that included both clearly autoimmune diseases (AID) and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology. Any = Any pIMD(s) regardless of intensity or relationship to vaccination. Related = pIMDs assessed by the investigator as causally related to the vaccination.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any and Related Serious Adverse Events (SAEs).","description":"Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. Any = Any SAE(s) regardless of intensity or relationship to vaccination. Related = SAEs assessed by the investigator as causally related to the vaccination.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":36,"n":2584},"commonTop":["Pain","Headache","Muscle aches","Nasopharyngitis","Fatigue"]}}}